Pharmacokinetics, Safety, and Tolerability of DA-302168S Tablets in Participants With Varying Degrees of Renal Impairment and Normal Renal Function

November 10, 2026 updated by: Chendu DIAO Pharmaceutical Group CO., LTD.

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of DA-302168S Tablets in Trial Participants With Varying Degrees of Renal Impairment and in Those With Normal Renal Function

This Phase 1 study is designed to evaluate the pharmacokinetics and safety of a single oral dose of DA-302168S in subjects with moderate renal impairment (with the possible inclusion of subjects with mild renal impairment), compared with age-, sex-, and body mass index (BMI)-matched subjects with normal renal function. The results of this study will provide scientific evidence to support appropriate clinical dosing recommendations for DA-302168S in subjects with renal impairment.

Study Overview

Status

Recruiting

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

32

Phase

  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Jiangsu
      • Suzhou, Jiangsu, China, 215000
        • Recruiting
        • The Second Affiliated Hospital of Soochow University
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Age 18-65 years inclusive at ICF signing, male or female; age matching (±10 years) between normal and renal impairment groups, with sex matching as far as possible (±1 participant per sex).
  • Weight and BMI at screening: male ≥50.0 kg, female ≥45.0 kg; BMI 19.0-30.0 kg/m² inclusive; weight matching (±10 kg) between normal and renal impairment groups.
  • Fertile female or male participants must agree to use reliable contraception for themselves and their partners during the study and for 90 days after dosing (see Appendix 3), and must not donate sperm or oocytes/eggs for assisted reproduction.
  • Able to understand the study procedures and methods, voluntarily sign the ICF, and willing to strictly comply with protocol requirements and complete the related procedures.

Exclusion Criteria:

  • History or family history of medullary thyroid carcinoma, thyroid C-cell hyperplasia, or MEN2; or screening serum calcitonin ≥50 ng/L.
  • History of chronic pancreatitis, or acute pancreatitis within 3 months before ICF signing.
  • History of acute gallbladder disease within 3 months before ICF signing.
  • Any malignancy within 5 years before ICF signing (except curatively treated basal cell carcinoma considered cured).
  • History of severe cardiovascular, neuropsychiatric, gastrointestinal, respiratory, urinary, endocrine, or other systemic disease within 1 year before ICF signing (e.g., acute myocardial infarction, major depression, gastric ulcer, uremia).
  • Investigator-judged dysphagia at screening, or conditions possibly affecting drug absorption, distribution, metabolism, or excretion (e.g., active inflammatory bowel disease, gastrectomy, any intestinal resection).
  • Severe hypoglycemia within 3 months before screening.
  • Participation in any clinical trial within 3 months before screening (except ICF signing only without drug/device intervention), or last dose of investigational drug <5 half-lives before screening.
  • History of allergic diseases (e.g., asthma, urticaria, eczematous dermatitis), or known intolerance/allergy to GLP-1 receptor agonists.
  • Major surgery within 1 year before screening [major surgery defined as surgery on intracranial, thoracic, abdominal, pelvic, or limb organs causing major tissue trauma and requiring prolonged recovery (e.g., organ transplantation, cardiac surgery, joint replacement)], or planned surgery during the study.
  • Blood donation or massive blood loss (≥400 mL) within 3 months before screening or between screening and first dose, or planned blood donation during the study.
  • History of drug abuse within 3 years before screening (e.g., morphine, ketamine, THC acid, methamphetamine, MDMA, cocaine) or positive baseline urine drug test.
  • Smoking >5 cigarettes/day or habitual use of nicotine-containing products within 3 months before screening, or inability to abstain during the study.
  • History of alcohol abuse within 1 year before screening (male >14 standard units/week, female >7 standard units/week; 1 standard unit = 14 g alcohol, e.g., 360 mL beer, 45 mL 40% spirits, or 150 mL wine), or positive baseline breath/blood alcohol test.
  • Special dietary requirements and inability to accept a standardized diet.
  • Consumption of grapefruit-rich beverages or foods within 7 days before first dose, or unwillingness to stop during the study.
  • Vaccination within 30 days before dosing, or planned vaccination within 30 days after dosing.
  • Inability to avoid strenuous exercise or other behaviors possibly affecting PK parameters from 48 h before dosing through the study.
  • History of needle/blood phobia, difficult blood collection, or intolerance to venipuncture.
  • Pregnant or lactating women.
  • Participant is an investigator or other related research staff for this project.
  • Any other condition that, in the investigator's opinion, makes the participant unsuitable for the study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Group A

Subjects with moderate renal impairment

Small molecule GLP-1RA tablet

Experimental: Group B

Subjects with moderate renal impairment

Small molecule GLP-1RA tablet

Placebo Comparator: Group C

Subjects with normal renal function matched to renal impairment subjects

Small molecule GLP-1RA tablet

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Peak Plasma Concentration (Cmax) of DA-302168S
Time Frame: Predose up to 72 hours postdose (D1 to D4)
Predose up to 72 hours postdose (D1 to D4)
Area Under the Serum Concentration Curve From Time 0 to the Last Measurable Concentration (AUC0-last) of DA-302168S
Time Frame: Predose up to 72 hours postdose (D1 to D4)
Predose up to 72 hours postdose (D1 to D4)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 2, 2026

Primary Completion (Estimated)

December 12, 2026

Study Completion (Estimated)

December 12, 2026

Study Registration Dates

First Submitted

November 10, 2026

First Submitted That Met QC Criteria

November 10, 2026

First Posted (Actual)

November 16, 2026

Study Record Updates

Last Update Posted (Actual)

November 16, 2026

Last Update Submitted That Met QC Criteria

November 10, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe